Incidence of hepatic dysfunction is equivalent in burn patients receiving oxandrolone and controls

Mona C. McCullough, Nicholas Namias, Carl Schulman, Ellie Gomez, Ron Manning, Seth Goldberg, Louis Pizano, Gillon C. Ward

Research output: Contribution to journalReview article

10 Scopus citations

Abstract

Oxandrolone has been shown to improve lean muscle mass in patients with burns. Hepatic dysfunction is a known side effect of treatment with oxandrolone. The purpose of this study was to examine the incidence of hepatic dysfunction in our series of burn patients receiving oxandrolone. Fourteen patients who received oxandrolone (5 mg, n = 8; 10 mg, n = 6) were identified from our prospectively collected burn database. The records of 61 control patients also were reviewed. Demographics such as age, comorbidities, and burn size were recorded. The incidence of hepatic dysfunction was determined by the presence of abnormal liver function tests. The study and control groups were similar in age and burn size. Two of the eight (25%) oxandrolone patients receiving 5 mg and four of the six (67%) oxandrolone patients receiving 10 mg had evidence of hepatic dysfunction. Twenty six of the 61 (43%) control patients had evidence of hepatic dysfunction (P = NS). There appears no significant increased incidence of hepatic dysfunction in burn patients who received oxandrolone compared to those who did not.

Original languageEnglish (US)
Pages (from-to)412-420
Number of pages9
JournalJournal of Burn Care and Research
Volume28
Issue number3
DOIs
StatePublished - May 1 2007

    Fingerprint

ASJC Scopus subject areas

  • Surgery
  • Emergency Medicine
  • Rehabilitation

Cite this